[go: up one dir, main page]

IL126463A0 - A pharmaceutical formulation containing growth hormone an amino acid and a non-ionic detergent - Google Patents

A pharmaceutical formulation containing growth hormone an amino acid and a non-ionic detergent

Info

Publication number
IL126463A0
IL126463A0 IL12646397A IL12646397A IL126463A0 IL 126463 A0 IL126463 A0 IL 126463A0 IL 12646397 A IL12646397 A IL 12646397A IL 12646397 A IL12646397 A IL 12646397A IL 126463 A0 IL126463 A0 IL 126463A0
Authority
IL
Israel
Prior art keywords
amino acid
growth hormone
ionic detergent
pharmaceutical formulation
formulation containing
Prior art date
Application number
IL12646397A
Other languages
English (en)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of IL126463A0 publication Critical patent/IL126463A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL12646397A 1996-04-24 1997-04-24 A pharmaceutical formulation containing growth hormone an amino acid and a non-ionic detergent IL126463A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK49096 1996-04-24
PCT/DK1997/000184 WO1997039768A1 (en) 1996-04-24 1997-04-24 A pharmaceutical formulation containing growth hormone, an amino acid and a non-ionic detergent

Publications (1)

Publication Number Publication Date
IL126463A0 true IL126463A0 (en) 1999-08-17

Family

ID=8094154

Family Applications (2)

Application Number Title Priority Date Filing Date
IL12646397A IL126463A0 (en) 1996-04-24 1997-04-24 A pharmaceutical formulation containing growth hormone an amino acid and a non-ionic detergent
IL126463A IL126463A (en) 1996-04-24 1998-10-04 Pharmaceutical preparation containing growth hormone, histidine and non-ionic detergent

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL126463A IL126463A (en) 1996-04-24 1998-10-04 Pharmaceutical preparation containing growth hormone, histidine and non-ionic detergent

Country Status (20)

Country Link
US (1) US20020077461A1 (xx)
EP (2) EP1629832A1 (xx)
JP (2) JP4176834B2 (xx)
KR (1) KR20000010630A (xx)
CN (1) CN1130223C (xx)
AT (1) ATE309819T1 (xx)
AU (1) AU733592B2 (xx)
BR (1) BR9708858A (xx)
CA (1) CA2252535C (xx)
CZ (1) CZ298292B6 (xx)
DE (1) DE69734653T2 (xx)
DK (1) DK0904099T3 (xx)
ES (1) ES2253774T3 (xx)
HU (1) HU229868B1 (xx)
IL (2) IL126463A0 (xx)
NO (1) NO323360B1 (xx)
PL (1) PL188222B1 (xx)
RU (1) RU2236250C2 (xx)
UA (1) UA66758C2 (xx)
WO (1) WO1997039768A1 (xx)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
EP0934061B3 (en) 1996-07-24 2015-01-21 Warner-Lambert Company LLC Isobutylgaba and its derivatives for the treatment of pain
CA2309818C (en) * 1997-11-12 2009-05-05 Alza Corporation Buffered drug formulations for transdermal electrotransport delivery
GB9803448D0 (en) * 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
JP4711520B2 (ja) * 2000-03-21 2011-06-29 日本ケミカルリサーチ株式会社 生理活性ペプチド含有粉末
WO2002011695A2 (en) 2000-08-07 2002-02-14 Inhale Therapeutic Systems, Inc. Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
EP1603588A2 (en) * 2003-03-18 2005-12-14 Ares Trading S.A. Stabilisation of growth hormones in solution
WO2004084703A2 (en) * 2003-03-24 2004-10-07 Biosphere Medical, Inc. Temporary embolization using inverse thermosensitive polymers
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US7700086B2 (en) * 2003-11-06 2010-04-20 Pluromed, Inc. Internal clamp for surgical procedures
ATE554792T1 (de) * 2003-12-23 2012-05-15 Pharmacia Corp Stabiles wachstumshormon-flüssigformulierung
ATE547121T1 (de) * 2004-04-07 2012-03-15 Ares Trading Sa Flüssigformulierung für wachstumshormone
CA2594561C (en) * 2004-12-22 2014-12-23 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid
CN101374536B (zh) * 2004-12-22 2013-09-25 Ambrx公司 包含非天然编码的氨基酸的人生长激素配方
NZ584597A (en) * 2004-12-22 2011-09-30 Ambrx Inc Modified human growth hormone
KR20080038391A (ko) 2005-08-30 2008-05-06 노보 노르디스크 헬스 케어 악티엔게젤샤프트 페그화 성장 호르몬의 액체 제제
WO2007033427A1 (en) * 2005-09-23 2007-03-29 Metabolic Pharmaceuticals Limited Stabilisation of peptides with basic amino acids
CN1939534B (zh) * 2005-09-27 2010-12-01 长春金赛药业股份有限公司 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂
EP2049148B1 (en) * 2006-07-06 2016-09-28 Daewoong Co., Ltd. A stable liquid formulation of human growth hormone
KR20100014215A (ko) 2006-07-07 2010-02-10 노보 노르디스크 헬스 케어 악티엔게젤샤프트 신규 단백질 접합체 및 그것의 제조 방법
EP2120869A2 (en) * 2006-12-18 2009-11-25 Altus Pharmaceuticals Inc. Human growth hormone formulations
US9211342B2 (en) 2010-01-22 2015-12-15 Novo Nordisk Healthcare Ag Stable growth hormone compounds resistant to proteolytic degradation
BR112012018116B1 (pt) 2010-01-22 2022-06-21 Novo Nordisk Health Care Ag Conjugados de hormônio do crescimento com eficácia in vivo prolongada
KR101337797B1 (ko) * 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
US8765411B2 (en) * 2010-09-21 2014-07-01 Ferring B.V. Process for production of recombinant human growth hormone from E. coli cells
US9216219B2 (en) * 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
KR20150034209A (ko) 2012-06-26 2015-04-02 델 마 파마슈티컬스 인코포레이티드 디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법
JP6464145B2 (ja) 2013-04-05 2019-02-06 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 成長ホルモン化合物製剤
AU2014251038A1 (en) 2013-04-08 2015-11-26 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
EP3024456A4 (en) 2013-07-26 2017-04-12 Update Pharma Inc. Combinatorial methods to improve the therapeutic benefit of bisantrene
MX2016003705A (es) * 2013-09-27 2016-05-16 Hanmi Pharm Ind Co Ltd Formulacion de un conjugado de hormona del crecimiento humana de accion prolongada.
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
SMT202300480T1 (it) 2016-03-28 2024-01-10 Incyte Corp Composti di pirrolotriazina come inibitori di tam
JP7188944B2 (ja) 2017-09-07 2022-12-13 Ｊｃｒファーマ株式会社 水性医薬組成物
EP3988552A1 (en) 2017-09-27 2022-04-27 Incyte Corporation Salts of pyrrolotriazine derivatives useful as tam inhibitors
SG11202013163TA (en) 2018-06-29 2021-01-28 Incyte Corp Formulations of an axl/mer inhibitor
US12214036B2 (en) 2020-03-06 2025-02-04 Incyte Corporation Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
CN115634284B (zh) * 2022-10-31 2025-02-11 景泽生物医药(合肥)股份有限公司 一种促性腺激素冻干制剂及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
EP0618807B1 (en) * 1991-12-20 2002-11-13 Novo Nordisk A/S A stabilized pharmaceutical formulation comprising growth hormone and histidine
ES2286868T3 (es) * 1992-07-31 2007-12-01 Genentech, Inc. Composicion acuosa a base de hormana del crecimiento humana.

Also Published As

Publication number Publication date
CN1130223C (zh) 2003-12-10
HUP9902476A3 (en) 2000-12-28
HUP9902476A2 (hu) 2000-11-28
KR20000010630A (ko) 2000-02-25
JP2000508665A (ja) 2000-07-11
PL188222B1 (pl) 2004-12-31
DE69734653T2 (de) 2006-08-10
DK0904099T3 (da) 2006-03-06
NO984951D0 (no) 1998-10-23
JP2008231124A (ja) 2008-10-02
AU2634397A (en) 1997-11-12
NO984951L (no) 1998-10-23
ATE309819T1 (de) 2005-12-15
ES2253774T3 (es) 2006-06-01
EP0904099B1 (en) 2005-11-16
CA2252535C (en) 2009-06-23
CN1216472A (zh) 1999-05-12
AU733592B2 (en) 2001-05-17
EP0904099A1 (en) 1999-03-31
RU2236250C2 (ru) 2004-09-20
EP1629832A1 (en) 2006-03-01
BR9708858A (pt) 1999-08-03
HU229868B1 (en) 2014-10-28
IL126463A (en) 2007-06-17
NO323360B1 (no) 2007-04-10
US20020077461A1 (en) 2002-06-20
UA66758C2 (en) 2004-06-15
CZ298292B6 (cs) 2007-08-15
DE69734653D1 (de) 2005-12-22
WO1997039768A1 (en) 1997-10-30
CZ320798A3 (cs) 1999-03-17
JP4176834B2 (ja) 2008-11-05
CA2252535A1 (en) 1997-10-30
PL329386A1 (en) 1999-03-29

Similar Documents

Publication Publication Date Title
IL126463A0 (en) A pharmaceutical formulation containing growth hormone an amino acid and a non-ionic detergent
EP1077070A3 (en) Oral drug delivery compositions
BR9913857A (pt) Formulações de proteìna
MD1699F2 (ro) Compoziţie apoasă a hormonului somatotrop uman şi procedeu de prevenire a denaturării ei
CA2314313A1 (en) Stabilized teriparatide solutions
WO2002043750A8 (en) Method for the stabilizing of biomolecules (e.g. insulin) in liquid formulations
AU2002223684A1 (en) Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
AR007715A1 (es) Formulacion acuosa estable de un peptido, un metodo para preparar la misma y su uso para tratamiento
NZ228747A (en) Stabilised pharmaceutical formulations comprising human growth hormone, glycine and mannitol
EP0643963A3 (en) Biologically erodible device for the administration of active substances.
WO1999032135A8 (en) Keratinocyte growth factor-2 formulations
ITMI913170A1 (it) Composizione farmaceutica per uso oftalmico contenente un antiinfiammatorio non steroideo ed un decongestionante come principi attivi
HUP0003840A2 (hu) Szabályozott hatóanyagleadású gyógyászati készítmények
CA2284774A1 (en) Theobromine antitussive compositions
EP0641216A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING IL-6.
AU621763B2 (en) Stable tretinoin emulsified cream formulations
GB9818973D0 (en) Method for preparing pharmaceutical formulations
AU6524298A (en) Pharmaceutical composition, containing medium-chain fatty acids as active ingredients, for dental caries and periodontal disease
RU97113620A (ru) Ранозаживляющая мазь "эпофен"
IT1247936B (it) Composizioni farmaceutiche per il trattamento di dermatosi
IT1255237B (it) Composizione farmaceuticaidrofila ad attivita' antiinfiammatoria
IT1254453B (it) Composizioni farmaceutiche per uso orale a base di glutatione ridotto

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed